ISSN: 0970-938X (Print) | 0976-1683 (Electronic)

Biomedical Research

An International Journal of Medical Sciences

Research Article - Biomedical Research (2018) Artificial Intelligent Techniques for Bio Medical Signal Processing: Edition-II

Effect of Gastrodia elata-notoginseng decoction on blood pressure variability and inflammatory factors in old hypertensive patients with yin-deficiency and yang-hyperactivity syndrome

Wang Dengqin1, Zhang Xiaoxue2, Song Guohong3, Li Lei4 and Sun Bing5*

1Clinical Medical Skills Center, Jining Medical University, PR China

2Department of Neurology, Jining City Hospital of Traditional Chinese Medicine, PR China

3Teaching-Research Office of Surgery, Jining Medical University, PR China

4Teaching-Research Office of Diagnostics, Jining Medical University, PR Chinas

5Teaching-Research Office of Traditional Chinese Medicine, Jining Medical University, PR China

*Corresponding Author:
Sun Bing
Teaching-Research Office of Traditional Chinese Medicine
Jining Medical University, PR China

Accepted on May 4, 2017

DOI: 10.4066/biomedicalresearch.29-16-2108

Visit for more related articles at Biomedical Research

Abstract

Objective: This research was aimed to explore the decoction ability of Gastrodia elata-notoginseng of blood pressure variability and inflammatory factors in old hypertensive patients with yin-deficiency and yang-hyperactivity syndrome.

Methods: Totally 80 hypertensive patients with yin-deficiency and yang-hyperactivity syndrome were randomly divided into control group (40 cases) and treatment group (40 cases). Two groups received Lamlodipine 2.5 mg q.d., one tablet daily), and the treatment group additionally received Gastrodia elatanotoginseng decoction. Both groups were continuously treated for 12 weeks.

Results: The treatment efficacy in treatment group (85.0%) was higher than control group (62.5%) and the difference was statistically significant (P<0.01). After treatment, various parameters of treatment group were significantly lower (P<0.01 or P<0.05) than that of control group, including 24 h systolic pressure standard deviation (24 h SSD), 24 h diastolic pressure standard deviation (24 h DSD), diurnal systolic pressure Standard Deviation (dSSD), nocturnal systolic pressure standard deviation (nSSD), 24 h mean systolic blood pressure (24 h SBP), serum resistin level, C-reactive protein (CRP) level and adiponectin level.

Conclusions: Compared with Western medicine therapy only, Gastrodia elata-notoginseng decoction can further decrease blood pressure.

Keywords

Gastrodia elata-notoginseng decoction, Yin-deficiency, Yang-hyperactivity syndrome, Hypertension, Inflammatory reaction, Blood pressure variability.

Introduction

As a common disease, hypertension is one of the cardiovascular diseases with the highest incidence in the world. Increased systolic pressure, high pulse pressure and blood pressure circadian dysrhythmias often occur in old people due to their atherosclerosis, increased stiffness, decreased elasticity of vessels, and hypofunction of blood pressure regulation center. In antihypertensive therapy, improvement of systolic pressure is as important as reduction of blood pressure, pressure variation and adverse events like target-organ damage [1,2]. Traditional Chinese medicine (TCM) therapy for hypertension has several advantages in syndrome differentiation treatment. The whole regulation, smooth pressure reduction, symptom improvement, target-organ protection, better combination with Western medicine, and attenuation synergia [3]. Gastrodia elata-notoginseng decoction contains sanchi flower, Gastrodia elata and Dendrobium officinale, which has the effect of nourishing liver and kidney as well as reducing blood pressure. Previous studies have shown that Gastrodia elata-notoginseng decoction can improve hypertensive patients with anxiety [4]. Here, we initially explored its mechanism of action through further observing intervention effect of Gastrodia elata-notoginseng decoction on old hypertensive patients with yin-deficiency and yang-hyperactivity syndrome, and monitoring changes in blood pressure variability and plasma vasoactive substance during treatment.

Materials and Methods

Diagnostic criteria of elderly essential hypertension was referred to the Guidelines for Prevention and Treatment of Hypertension in China (1999 trial): age ≥ 65, SBD ≥ 140 mmHg (1 mmHg=0.133 kPa) and/or DBP ≥ 90 mmHg [2]. If SBD ≥ 140 mmHg and DBP<90 mmHg, it is defined as Isolated Systolic Hypertension (ISH).

TCM differentiation criteria were referred to Good Clinical Practice of new TCM [5]. Primary symptoms: dizziness, headache, flushing, soreness and weakness of waist and knees. Minor symptoms: palpitation, palpitation, tinnitus, bitter taste, dry throax, amnesia, red tongue with little coating and fine pulse. With 3 primary symptoms or 2 minor symptoms above, patients can be diagnosed in assistance of tongue pulse.

Enrolment criteria

(1) Meeting diagnostic criteria of elderly essential hypertension; (2) patients with yin-deficiency and yanghyperactivity syndrome; (3) age 65~80, all genders; (4) informed consent.

Exclusion criteria

(1) Various secondary hypertensive patients with severe cardiovascular and cerebrovascular diseases; (2) psychopaths or patients with disturbance of intelligence who are unable to cooperate with observers; (3) patients with myocardial infarction, stroke and cardiac failure; (4) patients with severe allergic constitution, or patients allergic to known ingredients.

General data

80 elderly essential hypertensive patients treated in TCM department and cardiology department of Jining City Hospital of TCM from 2014 to 2016 were selected and randomly divided into control group (40 cases, 22 males and 18 females) and treatment group (40 cases, 21 males and 19 females). In control group, the mean age was 69.4 ± 5.8; Body Mass Index (BMI) was 24.68 ± 4.01 kg•m-2; mean duration was 11.8 ± 10.6 y; TCM symptom aggregate score was 25.68 ± 7.55 points. The hypertension grade of control group was divided into Grade 1 (n=11), Grade 2 (n=19) and Grade 3 (n=10). In treatment group, the mean age was 69.8 ± 5.9; body mass index (BMI) was 24.56 ± 3.97 kg•m-2; mean duration was 12.4 ± 11.6 y; TCM symptom aggregate score was 24.79 ± 7.65 points; the hypertension grade of treatment group was divided into Grade 1 (n=10), Grade 2 (n=19) and Grade 3 (n=11). There was no statistical significance of general data between groups (P>0.05).

Therapeutic method

Two groups received the same antihypertensive treatment (Lamlodipine 2.5 mg q.d., one tablet daily), and the treatment group additionally received Gastrodia elata-notoginseng decoction (sanchi flower 6 g, Gastrodia elata 10 g,Dendrobium officinale 6 g). Both groups were treated for 12 weeks continuously.

Observational index

(1) 24 h ambulatory blood pressure monitoring (24 hABPM): dynamic electrocardiogram and blood pressure monitor CB-2301-A was used with special procedure setting (recording every 30 min during 8:00-22:00 and every 60 min during 22:00-next 8:00). Numbers of effective readings counted for over 80% of monitoring times. BPV indexes included several standard deviations, such as 24 h systolic pressure standard deviation (24 h SSD), 24 h diastolic pressure standard deviation (24 h DSD), diurnal systolic pressure standard deviation (dSSD), diurnal diastolic pressure standard deviation (dDSD), nocturnal systolic pressure standard deviation (nSSD) and nocturnal diastolic pressure standard deviation (nDSD); (2) vascular endothelial function and inflammation index examining included levels of adiponectin, resistin and CRP. Double-antibody sandwich ABC-ELISA assay was adopted in testing adiponectin and resistin, while radioimmunoassay in testing CRP. Patients were tested before and after treatment by kits (Shanghai Senxiongbiotech industrial limited company, batch number 20150961).

Evaluation of therapeutically criterion in TCM syndrome. Significant: obvious improvement in signs and symptoms, therapeutic index ≥ 70%;

Effective

Improvement in signs and symptoms, 30% ≤ therapeutic index ≤ 70%;

Invalid

Little improvement in signs and symptoms, therapeutic index<30%;

Therapeutic index (n)=(score of prior treatment-score of post treatment)/score of prior treatment × 100%

Statistical approach

Statistical software SPSS 17.0 was used for data processing. (x̄ ± s) was adopted in measurement data. Independent-samples ttest was used in comparison among groups. Pairing t-test was used in intra-group comparison and chi-square test was used in enumeration data. It will be considered as statistical significance when P<0.05.

Results

Efficacy comparison of TCM syndrome between groups

Total effective rate of TCM syndrome in treatment group was 85.0%, which was higher than that of control group 62.5% (P<0.05, Table 1).

Group Cases Significant Effective Invalid Total effective rate
Treatment 40 24 (60.0) 10 (25.0) 6 (15.0) 34 (85.0)△
Control 40 18 (45.0) 11 (27.5) 11 (27.5) 30 (62.5)

Table 1. Efficacy comparison of TCM syndrome in patients (n (%)).

Comparison of mean ambulatory blood pressure between groups

Compared with prior treatment, post-treatment 24 h SBP and 24 h DBP decreased significantly (P<0.01). Meanwhile, 24 h SBP of treatment group was lower than that of control group (P<0.01, Table 2).

Index Group Cases Prior treatment Post treatment
24 h SBP Control 40 145.34 ± 7.15 130.12 ± 3.85**
Treatment 40 145.12 ± 6.76 123.54 ± 4.36**△
24 h DBP Control 40 78.71 ± 9.55 71.59 ± 7.64**
Treatment 40 80.42 ± 8.52 72.64 ± 6.31**

Table 2. Comparison of mean blood pressure of TCM syndrome in prior-treatment and post-treatment patients (mmHg, x̄ ± s).

Comparison of blood pressure variability in priortreatment and post-treatment patients

Compared with prior treatment, the value of post-treatment 24 h SSD, 24 h DSD, dSSD and nSSD decreased significantly(P<0.01). Meanwhile, 24 h SBP-SD, DSBP-SD and NSBP-SD of treatment group was significantly lower than that of control group (P<0.01, Table 3).

Index Group Cases Prior treatment Post treatment
24h SBP-SD Control 32 14.63 ± 3.65 12.19 ± 3.21**
Treatment 32 16.73 ± 7.90 10.95 ± 2.35**△
24h DBP-SD Control 32 9.82 ± 2.67 8.15 ± 2.45*
Treatment 32 10.63 ± 5.11 8.45 ± 1.76*
DSBP-SD Control 32 13.81 ± 4.04 11.16 ± 2.26**△
Treatment 32 16.06 ± 4.14 10.08 ± 2.67**
DDBP-SD Control 32 9.27 ± 2.77 8.78 ± 2.83
Treatment 32 9.21 ± 3.16 8.42 ± 2.78
NSBP-SD Control 32 12.47 ± 4.23 10.49 ± 3.76*
Treatment 32 13.65 ± 4.92 9.16 ± 3.77**△
NDBP-SD Control 32 9.57 ± 4.08 9.36 ± 3.98
Treatment 32 9.39 ± 3.82 8.96 ± 3.61

Table 3. Comparison of blood pressure variability inprior-treatment and post-treatment patients (mmHg, x̄ ± s).

Levels of adiponectin, resistin and CRP in patients

Compared with prior treatment, post-treatment levels of resistin and CRP significantly decreased while level of adiponectin increased (P<0.05). Besides, changes of adiponectin, resistin and CRP in treatment group was significantly larger than that of control group (P<0.05, Table 4).

Index Group Cases Prior treatment Post treatment
24 h SBP-SD Control 32 14.63 ± 3.65 12.19 ± 3.21**
Treatment 32 16.73 ± 7.90 10.95 ± 2.35**△
24 h DBP-SD Control 32 9.82 ± 2.67 8.15 ± 2.45*
Treatment 32 10.63 ± 5.11 8.45 ± 1.76*
DSBP-SD Control 32 13.81 ± 4.04 11.16 ± 2.26**△
Treatment 32 16.06 ± 4.14 10.08 ± 2.67**
DDBP-SD Control 32 9.27 ± 2.77 8.78 ± 2.83
Treatment 32 9.21 ± 3.16 8.42 ± 2.78
NSBP-SD Control 32 12.47 ± 4.23 10.49 ± 3.76*
Treatment 32 13.65 ± 4.92 9.16 ± 3.77**△
NDBP-SD Control 32 9.57 ± 4.08 9.36 ± 3.98
Treatment 32 9.39 ± 3.82 8.96 ± 3.61

Table 4. Levels of adiponectin, resistin and CRP in patients (x̄ ± s).

Discussion

Hypertension belongs to ranges of headache and giddiness in traditional Chinese medicine, and yin-deficiency and yanghyperactivity syndrome is most common in syndrome distribution [6,7]. Previous study showed that yin-deficiency and yang-hyperactivity syndrome was related to BPV in old hypertensive patients. Internal imbalance of yin and yang as well as disturbance of qi activity often leads to hypertension, while asthenia in origin and asthenia in superficiality is the basic pathogenies. Liver and kidney are the most important parts in action mechanism where liver are substantial yin and functional yang. With kidney failing to nourish liver (Yindeficiency- type kidney), liver is influenced, which leads to hyperactivity of liver-yang [8,9]. Therefore, clinical therapy focuses on calming the liver, supplementing yin and regulating blood-pressure.

Gastrodia elata-notoginseng decoction in this study contains Gastrodia elata, sanchi flower, Gastrodia elata and Dendrobium officinale. With natured and sweet feature, Gastrodia elata acts as the sovereign drug that has effects of relieving convulsion and spasm, calming liver and suppressing yang without impairing yin. With cool-natured and sweet feature, sanchi flower acts as the ministerial drug that has effects of clearing heat, calming liver, reducing blood pressure, activating and harmonizing Qi-blood, promoting blood circulation to remove blood stasis, regulating emotion and sleep, and enhancing blood pressure reduction. Dendrobium officinale acts as the assistant drug that has effects of nourishing stomach and yin, clearing heat, moistening lung, tonifying kidney, improving eyesight and strengthening waist.

Total effective rate of TCM syndrome in treatment group was 85.0%, which was higher than that of control group 62.5%. The result shows that Gastrodia elata-notoginseng decoction can significantly improve clinical symptoms in old hypertensive patients with yin-deficiency and yanghyperactivity syndrome.

BPV is defined as the change scope of blood pressure in a certain period, which is related to target-organ damage. Hypertension treatment focuses on reduction of mean blood pressure as well as blood pressure variability. In this study, 24 h SSD, 24h DSD, dSSD and nSSD of post treatment are significantly decreased than that of prior treatment (P<0.01). Based on comparison between groups, 24 h SBPV, dSBPV and nSBPV of treatment group are significantly lower than that of control group (P<0.01). In reduction of mean blood pressure, post-treatment 24 h SBP and 24 h DBP of both groups are significantly decreased than that of prior treatment (P<0.01). The scope of systolic pressure reduction of treatment group is larger than that of control group (P<0.01), indicating that combined with general treatment of Western medicine, Gastrodia elata-notoginseng decoction can further reduce blood pressure and improve BPV in old hypertensive patients with yin-deficiency and yang-hyperactivity syndrome.

Although the etiology and pathogenesis of hypertension is unclear, previous study has shown that cytokines play an important role in pathological process of hypertension [10]. As an important factor of vascular inflammation and endothelial injury, CRP has vital function to the direct development of hypertension, CRP is considered as an independent risk factor of hypertension [11]. Besides, resistin is also recognized as one cytokines in inflammatory response, which can affect regulation of endothelial function, induction of endothelial activation and expression of multiple cytokines [12]. These proinflammatory factors destruct vessel structure and function, finally leading to endothelium dysfunction. Adiponectin always acts as one cytokines with protective effect [13]. Beside anti-atherosclerosis and anti-inflammatory effect, it can regulate CRP expression in adipose tissue and adjust CRP level. Our study shows that post-treatment CRP and resistin levels are significantly decreased while adiponectin level is significantly increased, which is more obvious in treatment group. The result indicates that Gastrodia elata-notoginseng decoction has multiple anti-inflammatory effects on hypertensive patients such as harmful factors suppression and protective factors enhancement.

Our study shows that Gastrodia elata-notoginseng decoction has significant effect of blood pressure decrease, BPV reduction, clinical symptom improvement, CRP and resistin reduction, and adiponectin increase, which provides theoretical basis for TCM treatment in old hypertensive patients with yindeficiency and yang-hyperactivity syndrome.

Acknowledgement

Fund program: Science and Technology Development Project of Traditional Chinese Medicine in Shandong Province.

References